Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis.

Trial Profile

Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Prednisone
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 03 Dec 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as per ClinicalTrials.gov record.
    • 24 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top